CL2015002361A1 - Inhibidores quinazolínicos de formas mutadas activantes del receptor del factor de crecimiento epidérmico - Google Patents

Inhibidores quinazolínicos de formas mutadas activantes del receptor del factor de crecimiento epidérmico

Info

Publication number
CL2015002361A1
CL2015002361A1 CL2015002361A CL2015002361A CL2015002361A1 CL 2015002361 A1 CL2015002361 A1 CL 2015002361A1 CL 2015002361 A CL2015002361 A CL 2015002361A CL 2015002361 A CL2015002361 A CL 2015002361A CL 2015002361 A1 CL2015002361 A1 CL 2015002361A1
Authority
CL
Chile
Prior art keywords
quinazolinic
inhibitors
growth factor
factor receptor
epidermal growth
Prior art date
Application number
CL2015002361A
Other languages
English (en)
Inventor
David Yunzhi Li
Jiabing Wang
Zhenfan Yang
Qingbei Zeng
Xiaolin Zhang
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50288181&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2015002361(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of CL2015002361A1 publication Critical patent/CL2015002361A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

LA INVENCION SE REFIERE A COMPUESTOS DE FORMULA (L) O UNA DE SUS SALES FARMACÉUTICAMENTE ACEPTABLES, QUE POSEEN ACTIVIDAD INHIBITORIA FRENTE A FORMAS MUTADAS ACTIVANTES DE EGFR Y QUE SON, POR CONSIGUIENTE, UTILES POR SU ACTIVIDAD CONTRA EL CANCER Y EN MÉTODOS DE TRATAMIENTO DEL CUERPO HUMANO O ANIMAL. LA INVENCIÓN TAMBIÉN SE REFIERE A COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN Y A SU USO EN LA ELABORACION DE MEDICAMENTOS PARA EMPLEAR EN LA PRODUCCION DE UN EFECTO CONTRA EL CANCER EN UN ANIMAL DE SANGRE CALIENTE TAL COMO UN SER HUMANO.
CL2015002361A 2013-03-06 2015-08-21 Inhibidores quinazolínicos de formas mutadas activantes del receptor del factor de crecimiento epidérmico CL2015002361A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2013072250 2013-03-06

Publications (1)

Publication Number Publication Date
CL2015002361A1 true CL2015002361A1 (es) 2016-01-04

Family

ID=50288181

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2015002361A CL2015002361A1 (es) 2013-03-06 2015-08-21 Inhibidores quinazolínicos de formas mutadas activantes del receptor del factor de crecimiento epidérmico

Country Status (42)

Country Link
US (4) US9066979B2 (es)
EP (2) EP3342770B1 (es)
JP (1) JP5894714B1 (es)
KR (1) KR101645112B1 (es)
CN (1) CN105209456B (es)
AP (1) AP2015008696A0 (es)
AR (1) AR095039A1 (es)
AU (1) AU2014224382B2 (es)
BR (1) BR112015020787B1 (es)
CA (1) CA2901269C (es)
CL (1) CL2015002361A1 (es)
CR (1) CR20150450A (es)
CY (1) CY1119487T1 (es)
DK (1) DK2964638T3 (es)
DO (1) DOP2015000189A (es)
ES (1) ES2642201T3 (es)
GT (1) GT201500251A (es)
HK (1) HK1216315A1 (es)
HR (1) HRP20171689T1 (es)
HU (1) HUE034568T2 (es)
IL (1) IL240578B (es)
LT (1) LT2964638T (es)
MA (1) MA38380A1 (es)
ME (1) ME03041B (es)
MX (1) MX362247B (es)
MY (1) MY186126A (es)
NI (1) NI201500123A (es)
NO (1) NO2964638T3 (es)
PE (1) PE20152000A1 (es)
PH (1) PH12015501965A1 (es)
PL (1) PL2964638T3 (es)
PT (1) PT2964638T (es)
RS (1) RS56566B1 (es)
RU (1) RU2656597C2 (es)
SG (1) SG11201506487YA (es)
SI (1) SI2964638T1 (es)
TN (1) TN2015000368A1 (es)
TW (1) TWI543977B (es)
UA (1) UA115686C2 (es)
UY (1) UY35369A (es)
WO (1) WO2014135876A1 (es)
ZA (1) ZA201507353B (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2964638T3 (pl) * 2013-03-06 2018-01-31 Astrazeneca Ab Inhibitory chinazolinowe aktywujących zmutowanych postaci receptora epidermalnego czynnika wzrostu
PH12019500143A1 (en) 2013-08-23 2020-03-02 Neupharma Inc Certain chemical entities, compositions, and methods
EP3201190A4 (en) * 2014-10-01 2018-03-14 Sun Pharmaceutical Industries Ltd Crystalline form of afatinib dimaleate
WO2016133935A1 (en) 2015-02-17 2016-08-25 Neupharma, Inc. Certain chemical entities, compositions, and methods
CN105859641B (zh) * 2015-05-05 2018-11-16 杭州华东医药集团新药研究院有限公司 喹唑啉巴豆基化合物二马来酸盐的晶体及其制备方法和用途
CN105503906B (zh) * 2015-12-09 2018-09-11 上海宣创生物科技有限公司 一种三唑并吡嗪衍生物a晶型及其制备方法
CN105503905B (zh) * 2015-12-09 2018-09-11 上海宣创生物科技有限公司 一种三唑并吡嗪衍生物b晶型及其制备方法
CA3033370A1 (en) 2016-08-15 2018-02-22 Neupharma, Inc. Certain chemical entities, compositions, and methods
CN108658946B (zh) * 2017-03-28 2020-06-16 焦玉奇 新颖的喹唑啉抑制剂
CN107400094B (zh) * 2017-09-08 2020-04-03 贾玉庆 喹唑啉基羧酸酯类化合物及其用途
CN109721551B (zh) * 2017-10-30 2022-09-20 上海北卡医药技术有限公司 一种3,4-二氢-7-甲氧基-4-氧代喹唑啉-6-醇乙酸酯的制备方法
CN109721552B (zh) * 2017-10-30 2022-09-20 上海北卡医药技术有限公司 一种吉非替尼的制备方法
SG11202007492XA (en) * 2018-02-08 2020-09-29 Neupharma Inc Certain chemical entities, compositions, and methods
CN109438423A (zh) * 2018-09-12 2019-03-08 通化师范学院 一种肺癌靶向化合物azd-3759的合成工艺的新方法
US20220040180A1 (en) * 2018-09-14 2022-02-10 Spectrum Pharmaceuticals, Inc. Kits and methods for treating cancers
CN110903283B (zh) * 2018-09-17 2021-01-01 南京雷正医药科技有限公司 一种取代的喹唑啉类化合物、包含该化合物的药物组合物和该化合物的用途
WO2020057403A1 (zh) * 2018-09-18 2020-03-26 北京越之康泰生物医药科技有限公司 吲哚衍生物及其在医药上的应用
CN111747931A (zh) * 2019-03-29 2020-10-09 深圳福沃药业有限公司 用于治疗癌症的氮杂芳环酰胺衍生物
EA202192552A1 (ru) 2019-03-29 2021-12-17 Астразенека Аб Осимертиниб для применения в лечении немелкоклеточного рака легкого
CN110590683B (zh) * 2019-10-11 2022-08-19 山东四环药业股份有限公司 一种靶向药物azd3759中间体的制备方法
US20210161897A1 (en) 2019-11-12 2021-06-03 Astrazeneca Ab Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
US20230056604A1 (en) 2020-01-20 2023-02-23 Astrazeneca Ab Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
US20210369709A1 (en) 2020-05-27 2021-12-02 Astrazeneca Ab EGFR TKIs FOR USE IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER
CN111675700A (zh) * 2020-06-22 2020-09-18 通化师范学院 一种抗癌新药azd3759的制备方法
CN111662273A (zh) * 2020-06-22 2020-09-15 通化师范学院 一种酪氨酸激酶抑制剂azd3759的制备方法
CN111848584A (zh) * 2020-07-10 2020-10-30 江南大学 一种多取代喹唑啉类化合物及其应用
CN113943273A (zh) * 2020-07-17 2022-01-18 上海天慈国际药业有限公司 一种肺癌药物azd3759的制备方法
CN113135901A (zh) * 2021-04-12 2021-07-20 南京雷正医药科技有限公司 氘代的喹唑啉类盐酸盐化合物的晶型及其制备和应用
WO2023187037A1 (en) 2022-03-31 2023-10-05 Astrazeneca Ab Epidermal growth factor receptor (egfr) tyrosine kinase inhibitors in combination with an akt inhibitor for the treatment of cancer
WO2023209088A1 (en) 2022-04-28 2023-11-02 Astrazeneca Ab Bicyclic heteroaromatic compounds and their use in the treatment of cancer
WO2023209084A1 (en) 2022-04-28 2023-11-02 Astrazeneca Ab Condensed bicyclic heteroaromatic compounds and their use in the treatment of cancer
WO2023209090A1 (en) 2022-04-28 2023-11-02 Astrazeneca Ab Bicyclic heteroaromatic compounds and their application in the treatment of cancer
US20240116926A1 (en) 2022-04-28 2024-04-11 Astrazeneca Ab Heteroaromatic compounds
WO2024002938A1 (en) 2022-06-27 2024-01-04 Astrazeneca Ab Combinations involving epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
CN115813927A (zh) * 2022-07-06 2023-03-21 江苏晨泰医药科技有限公司 受体酪氨酸激酶抑制剂与联苯环辛二稀木脂素的联合用药及其用途
WO2024008929A1 (en) 2022-07-08 2024-01-11 Astrazeneca Ab Epidermal growth factor receptor tyrosine kinase inhibitors in combination with hgf-receptor inhibitors for the treatment of cancer

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
US5821332A (en) 1993-11-03 1998-10-13 The Board Of Trustees Of The Leland Stanford Junior University Receptor on the surface of activated CD4+ T-cells: ACT-4
US6242566B1 (en) 1994-02-10 2001-06-05 Board Of Trustees Of The Leland Stanford Junior University Ligand (ACT-4-L) to a receptor on the surface of activated CD4+ T-cells
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
GB9607729D0 (en) 1996-04-13 1996-06-19 Zeneca Ltd Quinazoline derivatives
AU2873999A (en) 1998-02-24 1999-09-06 Sisters Of Providence In Oregon Compositions containing an OX-40 receptor binding agent or nucleic acid encoding the same and methods for enhancing antigen-specific immune response
EE05627B1 (et) 1998-12-23 2013-02-15 Pfizer Inc. CTLA-4 vastased inimese monoklonaalsed antikehad
DE19911509A1 (de) 1999-03-15 2000-09-21 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
WO2001021594A1 (en) 1999-09-21 2001-03-29 Astrazeneca Ab Quinazoline compounds and pharmaceutical compositions containing them
DE10042058A1 (de) 2000-08-26 2002-03-07 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
US6656946B2 (en) 2000-08-26 2003-12-02 Boehringer Ingelheim Pharma Kg Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases
TWI324597B (en) 2002-03-28 2010-05-11 Astrazeneca Ab Quinazoline derivatives
EA009300B1 (ru) * 2002-03-30 2007-12-28 Бёрингер Ингельхайм Фарма Гмбх Унд Ко. Кг 4-(n-фениламино)хиназолины/-хинолины в качестве ингибиторов тирозинкиназы
ES2295639T3 (es) 2002-06-13 2008-04-16 Crucell Holland B.V. Agonistas del receptor ox40=(=cd134) y uso terapeutico descripcion.
CA2508660C (en) 2002-12-23 2013-08-20 Wyeth Antibodies against pd-1 and uses therefor
BRPI0413066A (pt) 2003-07-29 2006-10-17 Astrazeneca Ab derivado de quinazolina, ou um sal farmaceuticamente aceitável, ou um éster farmaceuticamente aceitável do mesmo, da fórmula i, uso e processo para a preparação do mesmo, composto, composição farmacêutica, e, métodos para a produção de um efeito antiproliferativo em um animal de sangue quente, para a prevenção ou tratamento de um tumor, para prover um efeito inibitório de tirosina quinase de egfr seletivo, e para tratar um cáncer em um animal de sangue quente
US20080234263A1 (en) 2003-09-16 2008-09-25 Laurent Francois Andre Hennequin Quinazoline Derivatives
EP1670782B1 (en) 2003-09-19 2007-02-14 AstraZeneca AB Quinazoline derivatives
WO2005028469A1 (en) 2003-09-19 2005-03-31 Astrazeneca Ab Quinazoline derivatives
WO2005097137A2 (en) 2004-03-31 2005-10-20 The Scripps Research Institute Advanced quinazoline based protein kinase inhibitors
ES2741573T3 (es) 2004-03-31 2020-02-11 Massachusetts Gen Hospital Método para determinar la respuesta del cáncer a tratamientos dirigidos al receptor del factor de crecimiento epidérmico
SI2439273T1 (sl) 2005-05-09 2019-05-31 Ono Pharmaceutical Co., Ltd. Človeška monoklonska protitelesa za programirano smrt 1 (PD-1) in postopki za zdravljenje raka z uporabo protiteles proti PD-1 samostojno ali v kombinaciji z ostalimi imunoterapevtiki
CN101175734B (zh) * 2005-05-12 2011-10-12 黄文林 一种作为抗肿瘤药物的喹唑啉衍生物及其制备方法
CN101175732B (zh) * 2005-05-12 2010-06-16 黄文林 一种喹唑啉衍生物的制备方法及用作制备治疗肿瘤疾病药物的应用
CN101248089A (zh) 2005-07-01 2008-08-20 米德列斯公司 抗程序性死亡配体1（pd-l1）的人单克隆抗体
CA2619037A1 (en) 2005-08-22 2007-03-01 Boehringer Ingelheim International Gmbh Bicyclic heterocycles medicaments comprising said compounds use and method for production thereof
EP1971601B1 (en) * 2005-11-15 2009-10-21 Array Biopharma Inc. N4-phenyl-quinazoline-4 -amine derivatives and related compounds as erbb type i receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases
TWI405756B (zh) 2005-12-21 2013-08-21 Array Biopharma Inc 新穎硫酸氫鹽
BRPI0602275A (pt) 2006-03-24 2007-11-27 Astrazeneca Ab derivado de quinazolina, composição farmacêutica, uso de um derivado de quinazolina, métodos para produzir um efeito anti-proliferativo em um animal de sangue quente e para tratar um cáncer em um animal de sangue quente e processo para a preparação de um derivado de quinalizona
WO2009101611A1 (en) 2008-02-11 2009-08-20 Curetech Ltd. Monoclonal antibodies for tumor treatment
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme PD-1 BINDING PROTEINS
CN101367793B (zh) 2008-09-26 2013-09-11 中国科学院广州生物医药与健康研究院 一种具有抗肿瘤活性的氨基喹唑啉衍生物及其盐类
WO2010061208A2 (en) 2008-11-03 2010-06-03 Astrazeneca Ab Therapeutic treatment 555
UA109108C2 (uk) 2008-12-09 2015-07-27 Дженентек, Інк. Антитіло до pd-l1 та його застосування для посилення функції t-клітин
US9050341B2 (en) 2009-07-14 2015-06-09 Natco Pharma Limited Methods of treating drug resistant and other tumors by administering 6,7-dialkoxy quinazoline derivatives
ES2646863T3 (es) 2009-11-24 2017-12-18 Medimmune Limited Agentes de unión específica contra B7-H1
EP2966075B1 (en) 2009-12-31 2019-02-27 Hutchison Medipharma Limited Certain triazolopyridines, compositions thereof and their use in the treatment of cancer.
CN101857618B (zh) 2010-06-13 2015-11-25 中国海洋大学 作为蛋白酪氨酸激酶抑制剂的一系列喹唑啉糖衍生物，其制备方法和应用
EP2609118B1 (en) 2010-08-23 2017-01-18 Board Of Regents, The University Of Texas System Anti-ox40 antibodies and methods of using the same
DK2699264T3 (en) 2011-04-20 2018-06-25 Medimmune Llc ANTIBODIES AND OTHER MOLECULES BINDING B7-H1 AND PD-1
KR102410078B1 (ko) 2012-05-31 2022-06-22 소렌토 쎄라퓨틱스, 인코포레이티드 Pd-l1에 결합하는 항원 결합 단백질
PL2964638T3 (pl) * 2013-03-06 2018-01-31 Astrazeneca Ab Inhibitory chinazolinowe aktywujących zmutowanych postaci receptora epidermalnego czynnika wzrostu

Also Published As

Publication number Publication date
ZA201507353B (en) 2017-03-29
TWI543977B (zh) 2016-08-01
IL240578A0 (en) 2015-09-24
TN2015000368A1 (en) 2017-01-03
UY35369A (es) 2014-08-29
WO2014135876A1 (en) 2014-09-12
GT201500251A (es) 2017-10-09
EP2964638A1 (en) 2016-01-13
DK2964638T3 (en) 2017-10-30
US20180016259A1 (en) 2018-01-18
KR101645112B1 (ko) 2016-08-02
ME03041B (me) 2018-10-20
EP3342770A1 (en) 2018-07-04
NZ710850A (en) 2020-09-25
US20150320751A1 (en) 2015-11-12
AP2015008696A0 (en) 2015-08-31
CR20150450A (es) 2015-12-01
CA2901269A1 (en) 2014-09-12
ES2642201T3 (es) 2017-11-15
CY1119487T1 (el) 2018-03-07
MA38380A1 (fr) 2017-01-31
AU2014224382A1 (en) 2015-09-03
RS56566B1 (sr) 2018-02-28
US20160340342A1 (en) 2016-11-24
CN105209456A (zh) 2015-12-30
PE20152000A1 (es) 2016-01-22
AR095039A1 (es) 2015-09-16
CN105209456B (zh) 2018-05-08
SG11201506487YA (en) 2015-09-29
NI201500123A (es) 2016-02-16
US20140255428A1 (en) 2014-09-11
CA2901269C (en) 2022-01-18
PH12015501965B1 (en) 2016-01-11
MX2015011818A (es) 2016-01-08
KR20150083782A (ko) 2015-07-20
US9375432B2 (en) 2016-06-28
EP2964638B1 (en) 2017-08-09
DOP2015000189A (es) 2015-08-31
PL2964638T3 (pl) 2018-01-31
US9718806B2 (en) 2017-08-01
JP5894714B1 (ja) 2016-03-30
NO2964638T3 (es) 2018-01-06
HUE034568T2 (en) 2018-02-28
BR112015020787B1 (pt) 2022-12-06
AU2014224382B2 (en) 2016-11-10
SI2964638T1 (sl) 2017-11-30
RU2015139513A (ru) 2017-04-10
RU2656597C2 (ru) 2018-06-06
HRP20171689T1 (hr) 2018-02-23
PT2964638T (pt) 2017-11-14
PH12015501965A1 (en) 2016-01-11
JP2016511225A (ja) 2016-04-14
LT2964638T (lt) 2017-12-27
UA115686C2 (uk) 2017-12-11
HK1216315A1 (zh) 2016-11-04
IL240578B (en) 2019-03-31
MY186126A (en) 2021-06-24
TW201520206A (zh) 2015-06-01
MX362247B (es) 2019-01-09
US9066979B2 (en) 2015-06-30
BR112015020787A2 (pt) 2017-07-18
EP3342770B1 (en) 2022-03-30

Similar Documents

Publication Publication Date Title
CL2015002361A1 (es) Inhibidores quinazolínicos de formas mutadas activantes del receptor del factor de crecimiento epidérmico
CL2018003681A1 (es) Derivados de ácido borónico y usos terapéuticos de los mismos
SV2018005687A (es) Derivados de dihidroimidazopirazinona usados en el tratamiento del cancer
NI201600144A (es) Derivados de quinoxalina utiles como moduladores del fgfr cinasa
CO2017006962A2 (es) Derivados de 2-anilinopirimidina sustituida como moudladores de egfr
CU20170089A7 (es) Derivados de quinazolina utilizados para tratar el vih
CL2016001895A1 (es) Compuestos
TR201901312T4 (tr) Mcl-1 proteinini inhibe eden tetrahidronaftalen türevleri.
CL2015003395A1 (es) Derivados pirazolopirrolidina y su uso en el tratamiento de la enfermedad
BR112016018555A8 (pt) Ciclopropilaminas como inibidores de lsd1, seu uso, composição farmacêutica que os compreende e método de inibição de lsd1
DOP2015000157A (es) Lactamas fusionadas de arilo y heteroarilo
GT201400063A (es) Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas
MX2016001587A (es) Inhibidores de kdm1a para el tratamiento de enfermedades.
UA116648C2 (uk) Фумарати як проліки та їх застосування при лікуванні різних захворювань
ECSP17013903A (es) Protein kinase c inhibitors and methods of their use
CL2019002900A1 (es) Análogos de benzoazepina como agentes inhibidores de la tirosina cinasa de bruton.
CY1122763T1 (el) Νεες ενωσεις ιμιδαζοπυριδαζινης και η χρηση αυτων
TR201910866T4 (tr) Kanser tedavisi için birleşik preparasyonlar.
MX2020003495A (es) Derivados de acido boronico y sintesis de los mismos.
CR20150653A (es) Compuestos nuevos para el tratamiento del cáncer
CO2017000011A2 (es) Derivados de quinolizinona como inhibidores de pi3k
DOP2016000297A (es) Composiciones farmacéuticas útiles para tratar enfermedades infecciosas
UY35745A (es) Derivados sustituidos de fenilalanina
ECSP16086247A (es) (s)-pirlindole y sus sales farmacéuticamente aceptables para uso en medicina
ECSP16096831A (es) Derivados de naftiridinadiona